Article
Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients
7 Jan 2020
Abstract excerpt
In the era of immunotherapies there is an urgent need to implement the use of circulating biomarkers in clinical practice to facilitate personalized therapy and to predict treatment response. We conducted a prospective study to evaluate the usefulness of circulating exosomal-PD-L1 in melanoma patients' follow-up. We studied the dynamics of exosomal-PD-L1 from 100 melanoma patients by using an enzyme-linked...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
